Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Lyra Therapeutics Inc stock (LYRA)

Buy Lyra Therapeutics Inc stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Lyra Therapeutics Inc is a biotechnology business based in the US. Lyra Therapeutics Inc shares (LYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Lyra Therapeutics Inc employs 109 staff and has a trailing 12-month revenue of around $1.7 million.

Our top picks for where to buy Lyra Therapeutics Inc stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Lyra Therapeutics Inc stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – LYRA. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Lyra Therapeutics Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 3.1 / 5: ★★★★★
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lyra Therapeutics Inc stock price (NASDAQ: LYRA)

Use our graph to track the performance of LYRA stocks over time.

Lyra Therapeutics Inc shares at a glance

Information last updated 2024-07-21.
Latest market close$0.28
52-week range$0.25 - $6.79
50-day moving average $0.31
200-day moving average $3.48
Wall St. target price$1.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.17

Is it a good time to buy Lyra Therapeutics Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyra Therapeutics Inc price performance over time

Historical closes compared with the close of $0.28 from 2024-07-19

1 week (2024-07-15) -8.20%
1 month (2024-06-21) 3.63%
3 months (2024-04-22) -94.63%
6 months (2024-01-22) -94.40%
1 year (2023-07-21) -91.57%
2 years (2022-07-22) -95.29%
3 years (2021-07-22) 7.09
5 years (2019-07-18) N/A

Lyra Therapeutics Inc financials

Revenue TTM $1.7 million
Gross profit TTM $-34,234,000
Return on assets TTM -38.1%
Return on equity TTM -95.93%
Profit margin 0%
Book value $1.27
Market Capitalization $17.1 million

TTM: trailing 12 months

Lyra Therapeutics Inc share dividends

We're not expecting Lyra Therapeutics Inc to pay a dividend over the next 12 months.

Lyra Therapeutics Inc share price volatility

Over the last 12 months, Lyra Therapeutics Inc's shares have ranged in value from as little as $0.2532 up to $6.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lyra Therapeutics Inc's is -0.005. This would suggest that Lyra Therapeutics Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lyra Therapeutics Inc has bucked the trend.

Lyra Therapeutics Inc overview

Lyra Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc.

Frequently asked questions

What percentage of Lyra Therapeutics Inc is owned by insiders or institutions?
Currently 0.704% of Lyra Therapeutics Inc shares are held by insiders and 87.912% by institutions.
How many people work for Lyra Therapeutics Inc?
Latest data suggests 109 work at Lyra Therapeutics Inc.
When does the fiscal year end for Lyra Therapeutics Inc?
Lyra Therapeutics Inc's fiscal year ends in December.
Where is Lyra Therapeutics Inc based?
Lyra Therapeutics Inc's address is: 480 Arsenal Way, Watertown, MA, United States, 02472
What is Lyra Therapeutics Inc's ISIN number?
Lyra Therapeutics Inc's international securities identification number is: US55234L1052
What is Lyra Therapeutics Inc's CUSIP number?
Lyra Therapeutics Inc's Committee on Uniform Securities Identification Procedures number is: 55234L105

More guides on Finder

Ask a question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site